fMRI(磁共振功能成像)对乳腺癌新辅助化疗评估的研究进展

【摘要】〓能够早期评估乳腺癌新辅助化疗疗效的方法很大程度上有助于病人治疗方案的制定,所以对于找寻精准且无创的方法的需求则日益上升。目前,MRI技术能够根据肿瘤大小、形态及强化程度等形态学变化对疗效进行评估,而且已有越来越多新兴技术能够从微观分子层面早期反映新辅助化疗后肿瘤变化,这些技术包括动态对比增强(DCE-MRI)、磁共振波谱(MRS)、磁共振弥散加权成像(DWI)、体素内不相干运动(IVIM)。作者综述MRI新技术在评估乳腺癌新辅助化疗疗效中的应用。

The progress of current magnetic resonance imaging methods for predicting the response of breast cancer to neoadjuvant chemotherapy

Reliable early assessment of breast cancer response to neoadjuvant therapy (NACT) would provide many benefits to personalize patient care , so the demand for accurate and noninvasive response biomarkers is increasing. Recently, MRI can assess the response according to the morphology changes, like tumor size, enhancement, et al. And now there are increasing numbers of promising MRI technology reflecting the change of tumor in micro-molecular level after neoadjuvant chemotherapy. These MRI technology includes DCE-MRI, MRS, DWI, IVIM. This review focuses on the role of MRI in predicting the efficacy of neoadjuvant chemotherapy for breast cancer.